

(clinical and laboratory testing); promote TB, MDR-TB, and TB/HIV prevention and integration into existing healthcare services; strengthen TB surveillance and monitoring and evaluation (M&E) and improve collaboration and coordination between TB and other programs, particularly HIV and COVID-19. Funding amounts for years 2–5 will be set at continuation.

**DATES:** The period for this award will be September 30, 2022 through September 29, 2027.

**FOR FURTHER INFORMATION CONTACT:**

Amy Bailey, Center for Global Health, Centers for Disease Control and Prevention, 5th/Floor Tung Shing Building, No 2, Ngo Quyen Street, Hoan Kiem District Hanoi, Vietnam, Telephone: 800-232-6348, email: [fue8@cdc.gov](mailto:fue8@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The single-source award will contribute to enhancing early and universal access to high quality prevention, diagnosis, and treatment services for TB, MDR-TB, and TB/HIV with the goal of ending TB in Vietnam by 2030.

The NLH/NTP is in a unique position to conduct this work as it is mandated by Vietnam Ministry of Health (MoH) with oversight and implementation of TB prevention and control activities in Vietnam. The NLH is the leading tertiary hospital in charge of examination and treatment of TB and lung diseases and steering TB and lung disease prevention and control activities throughout the country.

**Summary of the Award**

**Recipient:** National Lung Hospital (NLH)/National Tuberculosis Program (NTP).

**Purpose of the Award:** The purpose of this award is to support high quality TB, MDR-TB, and TB/HIV programs to strengthen and expand TB and MDR-TB quality-assured diagnostic capacity (clinical and laboratory testing); promote TB, MDR-TB, and TB/HIV prevention and integration into existing healthcare services; strengthen TB surveillance and M&E and improve collaboration and coordination between TB and other programs, particularly HIV and COVID-19.

**Amount of Award:** The approximate year 1 funding amount will be \$1,500,000 in Federal Fiscal Year (FFY) 2022 fund, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

**Authority:** This program is authorized under Public Law 108-25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

**Period of Performance:** September 30, 2022 through September 29, 2027.

Dated: February 1, 2022.

**Terrance Perry,**

*Chief Grants Management Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-02412 Filed 2-3-22; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP); SIP22-001, Process, Outcome, and Cost Evaluation of Free Sunscreen Dispensers in Outdoor Community Settings.

**Date:** April 26, 2022.

**Time:** 11:00 a.m.–6:00 p.m., EDT.

**Place:** Teleconference.

**Agenda:** To review and evaluate grant applications.

**For Further Information Contact:** Jaya Raman Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S107-B, Atlanta, Georgia 30341, Telephone: (770) 488-6511, Email: [JRaman@cdc.gov](mailto:JRaman@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-02381 Filed 2-3-22; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): RFA-PS-22-001, Implementing Pre-exposure Prophylaxis for HIV Prevention in Syringe Service Programs; RFA-PS-22-002, Implementation Research on Telehealth Strategies to Support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients; and RFA-PS-22-004, Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex with Men in a Transformational Era.

**Date:** March 30, 2022.

**Time:** 10:00 a.m.–5:00 p.m., EDT.

**Place:** Teleconference.

**Agenda:** To review and evaluate grant applications.

**For Further Information Contact:**

Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, 1600 Clifton Road, NE, Mailstop US8-1, Atlanta, Georgia